Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync implantable cardioverter defibrillator italian registry

Maurizio Gasparini, Maurizio Lunati, Mario Bocchiardo, Massimo Mantica, Edoardo Gronda, Maria Frigerio, Domenico Caponi, Angelo Carboni, Giuseppe Boriani, Gabriele Zanotto, Pier Antonio Ravazzi, Antonio Curnis, Andrea Puglisi, Catherine Klersy, Ilaria Vicini, Sergio Cavaglià

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The aim of this study was to evaluate ventricular arrhythmias occurring in recipients of the InSync ICD for the primary and secondary prevention of sudden death. The InSync ICD was implanted in 142 patients (128 men; mean age 65 ± 10 years) with heart failure (mean NYHA functional Class 3.0 ± 0.7) and wide QRS (mean 159 ± 33 ms). The underlying etiology was ischemic in 55%, idiopathic in 33%, and valvular or hypertensive cardiomyopathy in 12% of patients. The numbers of arrhythmic episodes/100 patient-months was computed with their 95% CI, assuming a Poisson distribution. Implants were performed in 48 (34%) patients who did not have an ACC/AHA guidelines Class I indication for ICD therapy. A total of 104 patients were compliant for follow-up visits. During a 9-month median (range 0.1-24) follow-up of 104 compliant patients, 19 experienced a total of 94 ventricular arrhythmias, all successfully interrupted or selfterminated, with a median number of two separate episodes, corresponding to a rate of 10 episodes/100 person-month (95% CI 8-12). A rate of 12 episodes/100 person-months (95% CI 10-15) was measured in the subgroup of patients with ACC/AHA class I indications, versus two episodes/100 person-months (95% CI 1-5) in the remainder of the population. Among 12 deaths, 9 were due to heart failure, I to a noncardiovascular cause, and 2 to unknown causes. The implantation of ICD in heart failure patients has been prominently extended to primary prevention. Patients without standard ICD indications experienced life-threatening arrhythmic events. The impact of ICD combined with cardiac resynchronization therapy on arrhythmic profile, mortality, and costs in this subgroup of patients need to be more precisely studied, with a particular focus on the various types of underlying heart disease.

Original languageEnglish
Pages (from-to)148-151
Number of pages4
JournalPACE - Pacing and Clinical Electrophysiology
Volume26
Issue number1 II
Publication statusPublished - Jan 1 2003

Fingerprint

Cardiac Resynchronization Therapy
Implantable Defibrillators
Registries
Therapeutics
Heart Failure
Primary Prevention
Cardiac Arrhythmias
Poisson Distribution
Sudden Death
Secondary Prevention
Cardiomyopathies
Heart Diseases
Guidelines
Costs and Cost Analysis

Keywords

  • Cardiac resynchronization therapy
  • Heart failure
  • Implantable cardioverter defibrillator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiac resynchronization and implantable cardioverter defibrillator therapy : Preliminary results from the InSync implantable cardioverter defibrillator italian registry. / Gasparini, Maurizio; Lunati, Maurizio; Bocchiardo, Mario; Mantica, Massimo; Gronda, Edoardo; Frigerio, Maria; Caponi, Domenico; Carboni, Angelo; Boriani, Giuseppe; Zanotto, Gabriele; Antonio Ravazzi, Pier; Curnis, Antonio; Puglisi, Andrea; Klersy, Catherine; Vicini, Ilaria; Cavaglià, Sergio.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 26, No. 1 II, 01.01.2003, p. 148-151.

Research output: Contribution to journalArticle

Gasparini, M, Lunati, M, Bocchiardo, M, Mantica, M, Gronda, E, Frigerio, M, Caponi, D, Carboni, A, Boriani, G, Zanotto, G, Antonio Ravazzi, P, Curnis, A, Puglisi, A, Klersy, C, Vicini, I & Cavaglià, S 2003, 'Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync implantable cardioverter defibrillator italian registry', PACE - Pacing and Clinical Electrophysiology, vol. 26, no. 1 II, pp. 148-151.
Gasparini, Maurizio ; Lunati, Maurizio ; Bocchiardo, Mario ; Mantica, Massimo ; Gronda, Edoardo ; Frigerio, Maria ; Caponi, Domenico ; Carboni, Angelo ; Boriani, Giuseppe ; Zanotto, Gabriele ; Antonio Ravazzi, Pier ; Curnis, Antonio ; Puglisi, Andrea ; Klersy, Catherine ; Vicini, Ilaria ; Cavaglià, Sergio. / Cardiac resynchronization and implantable cardioverter defibrillator therapy : Preliminary results from the InSync implantable cardioverter defibrillator italian registry. In: PACE - Pacing and Clinical Electrophysiology. 2003 ; Vol. 26, No. 1 II. pp. 148-151.
@article{5856458eea3f40a6ba381037a22e3b54,
title = "Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync implantable cardioverter defibrillator italian registry",
abstract = "The aim of this study was to evaluate ventricular arrhythmias occurring in recipients of the InSync ICD for the primary and secondary prevention of sudden death. The InSync ICD was implanted in 142 patients (128 men; mean age 65 ± 10 years) with heart failure (mean NYHA functional Class 3.0 ± 0.7) and wide QRS (mean 159 ± 33 ms). The underlying etiology was ischemic in 55{\%}, idiopathic in 33{\%}, and valvular or hypertensive cardiomyopathy in 12{\%} of patients. The numbers of arrhythmic episodes/100 patient-months was computed with their 95{\%} CI, assuming a Poisson distribution. Implants were performed in 48 (34{\%}) patients who did not have an ACC/AHA guidelines Class I indication for ICD therapy. A total of 104 patients were compliant for follow-up visits. During a 9-month median (range 0.1-24) follow-up of 104 compliant patients, 19 experienced a total of 94 ventricular arrhythmias, all successfully interrupted or selfterminated, with a median number of two separate episodes, corresponding to a rate of 10 episodes/100 person-month (95{\%} CI 8-12). A rate of 12 episodes/100 person-months (95{\%} CI 10-15) was measured in the subgroup of patients with ACC/AHA class I indications, versus two episodes/100 person-months (95{\%} CI 1-5) in the remainder of the population. Among 12 deaths, 9 were due to heart failure, I to a noncardiovascular cause, and 2 to unknown causes. The implantation of ICD in heart failure patients has been prominently extended to primary prevention. Patients without standard ICD indications experienced life-threatening arrhythmic events. The impact of ICD combined with cardiac resynchronization therapy on arrhythmic profile, mortality, and costs in this subgroup of patients need to be more precisely studied, with a particular focus on the various types of underlying heart disease.",
keywords = "Cardiac resynchronization therapy, Heart failure, Implantable cardioverter defibrillator",
author = "Maurizio Gasparini and Maurizio Lunati and Mario Bocchiardo and Massimo Mantica and Edoardo Gronda and Maria Frigerio and Domenico Caponi and Angelo Carboni and Giuseppe Boriani and Gabriele Zanotto and {Antonio Ravazzi}, Pier and Antonio Curnis and Andrea Puglisi and Catherine Klersy and Ilaria Vicini and Sergio Cavagli{\`a}",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "26",
pages = "148--151",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "1 II",

}

TY - JOUR

T1 - Cardiac resynchronization and implantable cardioverter defibrillator therapy

T2 - Preliminary results from the InSync implantable cardioverter defibrillator italian registry

AU - Gasparini, Maurizio

AU - Lunati, Maurizio

AU - Bocchiardo, Mario

AU - Mantica, Massimo

AU - Gronda, Edoardo

AU - Frigerio, Maria

AU - Caponi, Domenico

AU - Carboni, Angelo

AU - Boriani, Giuseppe

AU - Zanotto, Gabriele

AU - Antonio Ravazzi, Pier

AU - Curnis, Antonio

AU - Puglisi, Andrea

AU - Klersy, Catherine

AU - Vicini, Ilaria

AU - Cavaglià, Sergio

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The aim of this study was to evaluate ventricular arrhythmias occurring in recipients of the InSync ICD for the primary and secondary prevention of sudden death. The InSync ICD was implanted in 142 patients (128 men; mean age 65 ± 10 years) with heart failure (mean NYHA functional Class 3.0 ± 0.7) and wide QRS (mean 159 ± 33 ms). The underlying etiology was ischemic in 55%, idiopathic in 33%, and valvular or hypertensive cardiomyopathy in 12% of patients. The numbers of arrhythmic episodes/100 patient-months was computed with their 95% CI, assuming a Poisson distribution. Implants were performed in 48 (34%) patients who did not have an ACC/AHA guidelines Class I indication for ICD therapy. A total of 104 patients were compliant for follow-up visits. During a 9-month median (range 0.1-24) follow-up of 104 compliant patients, 19 experienced a total of 94 ventricular arrhythmias, all successfully interrupted or selfterminated, with a median number of two separate episodes, corresponding to a rate of 10 episodes/100 person-month (95% CI 8-12). A rate of 12 episodes/100 person-months (95% CI 10-15) was measured in the subgroup of patients with ACC/AHA class I indications, versus two episodes/100 person-months (95% CI 1-5) in the remainder of the population. Among 12 deaths, 9 were due to heart failure, I to a noncardiovascular cause, and 2 to unknown causes. The implantation of ICD in heart failure patients has been prominently extended to primary prevention. Patients without standard ICD indications experienced life-threatening arrhythmic events. The impact of ICD combined with cardiac resynchronization therapy on arrhythmic profile, mortality, and costs in this subgroup of patients need to be more precisely studied, with a particular focus on the various types of underlying heart disease.

AB - The aim of this study was to evaluate ventricular arrhythmias occurring in recipients of the InSync ICD for the primary and secondary prevention of sudden death. The InSync ICD was implanted in 142 patients (128 men; mean age 65 ± 10 years) with heart failure (mean NYHA functional Class 3.0 ± 0.7) and wide QRS (mean 159 ± 33 ms). The underlying etiology was ischemic in 55%, idiopathic in 33%, and valvular or hypertensive cardiomyopathy in 12% of patients. The numbers of arrhythmic episodes/100 patient-months was computed with their 95% CI, assuming a Poisson distribution. Implants were performed in 48 (34%) patients who did not have an ACC/AHA guidelines Class I indication for ICD therapy. A total of 104 patients were compliant for follow-up visits. During a 9-month median (range 0.1-24) follow-up of 104 compliant patients, 19 experienced a total of 94 ventricular arrhythmias, all successfully interrupted or selfterminated, with a median number of two separate episodes, corresponding to a rate of 10 episodes/100 person-month (95% CI 8-12). A rate of 12 episodes/100 person-months (95% CI 10-15) was measured in the subgroup of patients with ACC/AHA class I indications, versus two episodes/100 person-months (95% CI 1-5) in the remainder of the population. Among 12 deaths, 9 were due to heart failure, I to a noncardiovascular cause, and 2 to unknown causes. The implantation of ICD in heart failure patients has been prominently extended to primary prevention. Patients without standard ICD indications experienced life-threatening arrhythmic events. The impact of ICD combined with cardiac resynchronization therapy on arrhythmic profile, mortality, and costs in this subgroup of patients need to be more precisely studied, with a particular focus on the various types of underlying heart disease.

KW - Cardiac resynchronization therapy

KW - Heart failure

KW - Implantable cardioverter defibrillator

UR - http://www.scopus.com/inward/record.url?scp=0346665533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346665533&partnerID=8YFLogxK

M3 - Article

C2 - 12687801

AN - SCOPUS:0346665533

VL - 26

SP - 148

EP - 151

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 1 II

ER -